罕见遗传病 - - 亨廷顿胆病的阿育吠陀治疗:一个病例报告
Mahesh Sharma1, Sourabh Deshmukh2, Trupti Thakre3
1PG Scholar, Kayachikitsa Department; Mahatma Gandhi Ayurved College Hospital and Research Centre, Salod (H), Wardha, Maharashtra, India.
Alternative therapies in health and medicine
|July 15, 2025
概括
阿育吠陀治疗显著改善了亨廷顿氏病患者的运动功能,行为健康和日常生活活动. 这份病例报告强调了阿育吠陀在治疗这种进展性神经退行性疾病方面的潜力.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 综合医学是一个整体的医学.
背景情况:
- 亨廷顿胆固醇是一种进展性神经退行性疾病,由HTT基因CAG重复扩张引起.
- 它导致运动,认知和精神障碍,严重影响生活质量.
研究的目的:
- 为了强调亨廷顿病的渐进性质.
- 评估阿育吠陀治疗对改善亨廷顿氏病冠状病患者生活质量的作用.
主要方法:
- 一个40岁的男性被诊断出患有亨廷顿氏胆核病的病例报告.
- 治疗包括阿育吠陀净化 (shodhana),外部疗法和口服药物,持续4个月.
主要成果:
- 阿育吠陀的管理导致了行为健康,神经运动功能和日常生活活动的实质性改善.
- 使用Sydenham的Chorea评分表 (USCRS) 来评估改善情况,该评分表使用了Minas Gerais联邦大学 (UFMG) 的Chorea评分表.
结论:
- 艾尔维达干预措施在控制亨廷顿病胆固醇症状方面显示出积极的结果.
- 这一案例表明,阿育吠陀在改善患者福祉和生活质量方面具有潜在的益处.
相关概念视频
Parkinson's Disease: Treatment
385
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
385
Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
902
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
902
Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715
Cholinergic Antagonists: Therapeutic Uses
880
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
880
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
843
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
843


